ID   KMS-21-BM
AC   CVCL_2991
SY   KMS-21BM; KMS21BM; Kawasaki Medical School-21-Bone Marrow
DR   EFO; EFO_0006614
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03152019
DR   BioSample; SAMN03472923
DR   BioSample; SAMN10987817
DR   cancercelllines; CVCL_2991
DR   Cell_Model_Passport; SIDM01658
DR   CGH-DB; 30-1
DR   CGH-DB; 9143-4
DR   DepMap; ACH-000598
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM887224
DR   GEO; GSM888298
DR   IARC_TP53; 30103
DR   JCRB; JCRB1185
DR   JCRB; NIHS0485
DR   LiGeA; CCLE_778
DR   PharmacoDB; KMS21BM_767_2019
DR   Progenetix; CVCL_2991
DR   Wikidata; Q54900172
RX   CelloPub=CLPUB00604;
RX   DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX   PubMed=11697507;
RX   PubMed=12592342;
RX   PubMed=15215163;
RX   PubMed=20143388;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32123307;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Problematic cell line: Misclassified. Originally thought to be a myeloma cell line and to be a sister line to KMS-21-PE (Cellosaurus=CVCL_A445) but this does not seem to be the case (PubMed=12592342; PubMed=20143388).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00228.
CC   Population: Japanese.
CC   HLA typing: A*24:02,24:02; B*40:01,40:01; C*01:02,03:04 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (DepMap=ACH-000598).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=78.63%; East Asian, South=21.2%; South Asian=0.16%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0485; true.
ST   Source(s): JCRB=JCRB1185; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,14
ST   D16S539: 9
ST   D18S51: 13
ST   D21S11: 31,32.2
ST   D3S1358: 15,17
ST   D5S818: 10,11
ST   D7S820: 8,13
ST   D8S1179: 12
ST   FGA: 19,22,23
ST   Penta D: 9,10
ST   Penta E: 11,12
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Undefined cell line type
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 33
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017); University of Toronto; Toronto; Canada.
//
RX   DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RA   Otsuki T., Yamada O., Yata K., Nakazawa N., Taniwaki M., Sakaguchi H.,
RA   Yawata Y., Ueki A.;
RT   "Genetic and biological characterization of human myeloma cell lines:
RT   an overview of the lines established at Kawasaki Medical School.";
RL   Gene Funct. Dis. 1:48-56(2000).
//
RX   PubMed=11697507; DOI=10.3109/10428190109099339;
RA   Otsuki T., Wada H., Nakazawa N., Taniwaki M., Kouguchi K., Ohkura M.,
RA   Uehira K., Isoda K., Yata K., Sakaguchi H., Yawata Y., Ueki A.,
RA   Yamada O.;
RT   "Establishment of CD7+ human myeloma sister cell lines, KMS-21-PE and
RT   KMS-21-BM, carrying t(11;14) and t(8;14).";
RL   Leuk. Lymphoma 42:761-774(2001).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2; PMCID=PMC1618545;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C.,
RA   Yang H.H., Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//